News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

  • In a nationwide study of women with triple-negative breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of patients whose tumors shrank away completely.

Tags: chemotherapy, BreastCancer

  • Women being treated with breast cancer drugs known as aromatase inhibitors can markedly ease the joint pain associated with the drugs by engaging in moderate daily exercise, Dana-Farber Cancer Institute and Yale University investigators report in a study to be presented during the San Antonio Breast Cancer Symposium.

Tags: BreastCancer, Exercise

  • In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment.

Tags: chemotherapy, BreastCancer, TargetedTherapy

  • Dana-Farber researchers and their colleagues report a toxin linked to a targeted monoclonal antibody has shown antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment.

Tags: Lymphoma

  • Children with acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer, can safely receive intravenous infusions of a reformulated mainstay of chemotherapy that has been delivered via painful intramuscular injection for more than 40 years, research suggests.

Tags: chemotherapy, ChildhoodCancer, Leukemia

  • Dana-Farber researchers found that adding bortezomib to initial treatment for chronic graft-versus-host disease allowed significant reduction of steroid medication in some patients.

Tags: GraftVersusHost, StemCellTransplant

  • Dana-Farber researchers identify a specific mutation that switches on Waldenström's Macroglobulinemia in one-third of patients, and a drug that targets the mutation — which could lead to better treatments for those patients.

Tags: Genetics, Lymphoma

  • Dana-Farber researchers found an experimental drug blocked vulnerable cell growth pathways in a diverse group of aggressive B cell lymphomas, suggesting a potential new avenue for treating the most common type of non-Hodgkin lymphoma.

Tags: Lymphoma

  • Dana-Farber researchers find adding bortezomib to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for some patients.

Tags: GraftVersusHost, StemCellTransplant

  • Dana-Farber/Boston Children's researchers reported promising outcomes data for the first group of boys with X-linked severe combined immunodeficiency syndrome (SCID-X1), a fatal genetic immunodeficiency also known as "bubble boy" disease, who were treated in an international clinical study of a new form of gene therapy.

Tags: ChildhoodCancer, ImmuneSystem, Genetics, Leukemia

Showing 31-40 of 484 items